FzioMed Granted Patent Expanding Oxiplex ® Technology in Drug Delivery and Hemostasis

SAN LUIS OBISPO, California – August 11, 2005 – FzioMed, Inc. announced today the issuance of United States patent 6,923,961 which broadens coverage for the company’s proprietary Oxiplex technology in the fields of drug delivery and hemostasis.

Oxiplex is a versatile synthetic biomaterial developed by FzioMed for use in a wide variety of surgical specialties. The new patent relates to compositions of Oxiplex combined with drugs such as thrombin, and methods for their manufacture as well as their use in the control of bleeding during surgery.

“Oxiplex has significant advantages over the current generation of biomaterials being used for drug delivery and hemostasis,” said Richard Berg, Ph.D., Vice President of Research and Development for FzioMed, Inc. “These product development programs, together with this patent, strengthen FzioMed’s proprietary position for the development of innovative biosurgery products.”

FzioMed is a privately held medical company engaged in the development and commercialization of synthetic, absorbable biomaterials based on the company’s patented Oxiplex technology. FzioMed is developing products for the prevention of postsurgical adhesions, tissue augmentation and regeneration, and the delivery of drugs. Oxiplex is an innovative polymer technology with potential uses across a wide variety of specialties including orthopedics, gynecology, general surgery, cardiac, neurosurgery and aesthetic surgery. FzioMed products include Oxiplex/SP Gel, the leading adhesion barrier for spine surgery currently marketed outside of the United States, Oxiplex/AP adhesion barrier for abdominal/pelvic surgery, and a cosmetic dermal filler. Other FzioMed products are in various stages of development and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery materials.

FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.